Chapter

Systemic isotope therapy of bone metastasis

Christopher C Parker

in Systemic Treatment of Prostate Cancer

Published on behalf of Oxford University Press

ISBN: 9780199561421
Published online May 2011 | e-ISBN: 9780199607372 | DOI: http://dx.doi.org/10.1093/med/9780199561421.003.0009

Series: Oxford Oncology Library

Systemic isotope therapy of bone metastasis

Show Summary Details

Preview

• Sr-89 or Sm-153 improve pain control and quality of life, and delay the onset of new bone pain in men with CRPC and bone metastases • Sr-89 or Sm-153 are recommended as standard of care in current prostate cancer treatment guidelines • Sr-89 or Sm-153 may have a useful role not just in pain relief, but also in the prevention of skeletal-related events • Sr-89 and Sm-153 can cause haematologic toxicity, and should not normally be used in men who are likely to require cytotoxic chemotherapy • Ra-223 is a bone seeking alpha emitter, which may offer a better therapeutic ratio, with less myelosuppression.

Chapter.  2476 words.  Illustrated.

Subjects: Clinical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.